지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Usually, it takes at least 8 years to develop new drugs. Especially, the clinical trials are required to spend about 5 years. In America, the whole steps for new drug development are provided thoroughly in statutes and regulations of FDA. Most of all, in this paper, I explored FDA’s regulations on the preclinical trials, Good Laboratory Practices, and FDA’s laws & regulations on the clinical trials that are the essential aspects in the new drug development. In order to protect the rights, safeties and welfares of the human research subjects in the clinical trials, FDA established very detailed provisions in the Code of Federal Regulations delegated by the relevant statutes. As mentioned earlier, FDA has exerted itself in recent years to ensure the safety as well as the speedy development of new drugs. The latter has been achieved by enacting PDUFA in 1992(now PDUFA IV from 2008 till 2012), the former is achieved by the thorough FDA regulations on the clinical trials.
This paper consists of four chapters. Chapter Ⅰ describes the power of FDA on regulating the whole procedures of new drug development, the history of FDA’s laws and regulations on new drug development, and the purpose of this paper. Chapter Ⅱ examines the purpose, function, and contents of the preclinical trials and Good Laboratory Practices(GLPs). In addition, the methods of sanctions are explored when the clinical sponsor cannot comply with the GLPs. Chapter Ⅲ reveals the details relating to the clinical trials. It includes the contents of Investigational New Drug Application(IND), Informed Consent, IRB, the phases of the clinical trials, sponsor’s collaboration with FDA regarding clinical trials, obligations of clinical sponsors and investigators, expanded access to investigational drugs, clinical hold, IND termination and suspension. Chapter Ⅳ summaries the above mentioned contents in the first half. In the second half, I suggest that the status of KFDA’s guidances is required to be enhanced to the status of C.F.R. in America because they are related to the protection of the rights, safeties and welfares of the human research subjects in clinical trials.
This paper consists of four chapters. Chapter Ⅰ describes the power of FDA on regulating the whole procedures of new drug development, the history of FDA’s laws and regulations on new drug development, and the purpose of this paper. Chapter Ⅱ examines the purpose, function, and contents of the preclinical trials and Good Laboratory Practices(GLPs). In addition, the methods of sanctions are explored when the clinical sponsor cannot comply with the GLPs. Chapter Ⅲ reveals the details relating to the clinical trials. It includes the contents of Investigational New Drug Application(IND), Informed Consent, IRB, the phases of the clinical trials, sponsor’s collaboration with FDA regarding clinical trials, obligations of clinical sponsors and investigators, expanded access to investigational drugs, clinical hold, IND termination and suspension. Chapter Ⅳ summaries the above mentioned contents in the first half. In the second half, I suggest that the status of KFDA’s guidances is required to be enhanced to the status of C.F.R. in America because they are related to the protection of the rights, safeties and welfares of the human research subjects in clinical trials.
목차
Ⅰ. 머리말
Ⅱ. 전임상시험과 전임상시험관리기준
Ⅲ. 임상시험 및 구체적 내용
Ⅳ. 맺는말
참고문헌
Abstract
참고문헌 (17)
참고문헌 신청
2. [학술지(정기간행물)] - 박수헌 / 2008 / 신약승인체계에 대한 미연방 식품의약품청의 규제 / 토지공법연구 40 : 337 ~ 360
3. [보고서] - 박실비아 / 2007 / 의약품 사전상담제도 운영방안 연구
4. [학술지(정기간행물)] - 손동렬 / 2004 / 신약의 개발과 임상시험 / 순천향의대논문집 10 (1)
5. [단행본] - 이기형 / 2005 / FDA vs. 식약청 / 청년의사
6. [단행본] - B. David Naidu / 2009 / Biotechnology & Nanotechnology-Regulation Under Environmental, Health, and Safety Laws / Oxford University Press
3. [보고서] - 박실비아 / 2007 / 의약품 사전상담제도 운영방안 연구
4. [학술지(정기간행물)] - 손동렬 / 2004 / 신약의 개발과 임상시험 / 순천향의대논문집 10 (1)
5. [단행본] - 이기형 / 2005 / FDA vs. 식약청 / 청년의사
6. [단행본] - B. David Naidu / 2009 / Biotechnology & Nanotechnology-Regulation Under Environmental, Health, and Safety Laws / Oxford University Press
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
의약품 임상시험에서 피험자 보호
의료법학
2012 .01
-
의약품 임상시험의 계약적 일고찰
의료법학
2011 .01
-
임상시험의 정당화 요건과 형법적 통제
법학연구
2015 .12
-
임상시험 관련 법제의 문제점과 개선방안
동북아법연구
2020 .01
-
말기 암 환자에 대한 임상시험과 피험자의 자기결정권의 본질
의료법학
2014 .01
-
신약승인신청에 관한 미연방 식품의약품청의 규제명령에 관한 고찰
법학연구
2011 .11
-
임상시험과 피험자보호에 관한 연구
홍익법학
2014 .01
-
의약품 임상시험에서의 피험자의 자기결정권 확보방안
동아법학
2010 .02
-
미성년자 대상 임상시험에 관한 법적 문제점
의료법학
2016 .01
-
임상시험,의학적 연구와 관련한 국가,기관위원회 구성의 적정성 및 시험자,의뢰자에 대한 실효적 형사처벌필요성
비교형사법연구
2018 .01
-
임상시험비용에 대한 국민건강보험재정 지원에 관한 문제점 고찰
동북아법연구
2019 .01
-
마약류 수요억제 및 마약류 사범 처우합리화를 위한 종합대책
형사정책연구원 연구총서
2005 .12
-
임상시험 대상자 모집방법에 관한 법적·윤리적 검토
저스티스
2020 .06
-
Drug Situation and Drug Control in Korea
형사정책연구
1994 .09
-
불면증 무작위배정 임상시험에 대한 문헌 고찰
동의신경정신과학회지
2013 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2013-360-000498055